Innovative vaccines for a healthier world

We want to transform healthcare by developing novel vaccines that are life-saving and improving quality of life around the world.

Interview with CEO Bent Frandsen

Explore ExpreS2ion Biotechnologies, an innovator within biotechnology.
In a detailed interview, CEO Bent Frandsen outlines our progress in developing innovative vaccines for a healthier world.
Uncover the substantial impact of our pioneering work and the compelling reasons to invest.
Engage with us as we lead in transformative solutions through the advanced capabilities of ExpreS2ion Biotechnologies.
 

Next Event

  • Tue
    23
    Apr
    2024
    Thu
    25
    Apr
    2024

    Immune-Oncology Summit Europe

    London, UK

    We look forward to attending Cambridge Healthtech Institute's Inaugural event - Therapeutic Cancer Vaccines - showcasing Immunological Advances for Cancer Treatment.

    ExpreS2ion CSO Farshad Guirakhoo will be speaking on Preclinical Proof Of Concept Studies of a Novel Human HER-2 Virus Like Particle as a Vaccine Candidate for Human Breast Cancers on April 23 at 4:30pm in the session on Peptide-Based Vaccines.

    Learn more on Immune-Oncology Europe.

     

Latest News

ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023

Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces that the Board of Directors of ExpreS2ion has resolved to postpone the Company's annual general meeting and consequently also the publication of the annual report for 2023 due to administrative and practical reasons.

Read more

ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate

Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce the completion of the final report for the Good Laboratory Practice (GLP) safety study in non-human primates of the ES2B-C001 (HER2-VLP) breast cancer vaccine candidate.

Read more

ExpreS2ion to present in investor and R&D events in March

Hørsholm, Denmark, 15 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in investor and R&D events during March.

Read more